药物基因组分析表明B细胞发育状态和MKL1是对抗CD20单克隆抗体治疗敏感性的决定因素
George W Small1, Farida S Akhtari2, Adrian J Green3
1Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Cells
|June 28, 2023
概括
遗传因素,如MKL1基因变异和B细胞发育影响抗CD20单克隆抗体 (mAb) 治疗反应. 皮质类固醇治疗前可以提高B细胞疾病的治疗效率.
科学领域:
- 免疫学 免疫学 免疫学
- 药物基因组学 药物基因组学
- 遗传学 遗传学 是一个
背景情况:
- 针对CD20的单克隆抗体 (mAb) 治疗对于B细胞疾病至关重要.
- 患者的可变反应和抗CD20 mAb治疗的耐药性存在临床挑战.
研究的目的:
- 确定影响对CD20 mAb治疗敏感性的遗传因素.
- 探索患者对利图西马布,奥法图穆马布和奥比努图祖马布的反应的药物基因学基础.
主要方法:
- 在680个不同的淋巴细胞类细胞系 (LCL) 中对CD20 mAb细胞毒性的高通量查.
- 全基因组关联研究 (GWAS) 分析和定量PCR (qPCR) 用于遗传变异识别和基因表达.
- 使用shRNA介导的淘汰和流细胞计的功能验证.
主要成果:
- GWAS确定了新型基因候选者,MKL1基因中的rs58600101显示了种族分层和MKL1转录水平的降低.
- MKL1的淘汰导致了对CD20 mAb治疗更具抵抗力的表型.
- TGFB1I1被确定为与敏感性相关的重要基因;观察到免疫球蛋白类交换和B细胞激活标记物的差异.
- 耐药细胞系显示出向IgG+细胞的转变,并且前尼索隆预治疗部分逆转了耐药性.
结论:
- 抗CD20 mAb治疗的有效性可能会受到B细胞发育状态和MKL1基因多态化的影响.
- 使用皮质类固醇 (如普雷尼索隆) 进行预治疗可能会增强抗CD20 mAb治疗的临床益处.
相关概念视频
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...